Advanced glycation end products: A molecular target for vascular complications in diabetes

Molecular Medicine

Volumn 21, Issue , 2015, Pages S32-S40

  Yamagishi, Sho Ichi ^a   Nakamura, Nobutaka ^a   Suematsu, Mika ^a,b   Kaseda, Kuniyoshi ^b   Matsui, Takanori ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Saravio Central Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALAGEBRIUM; ALPHA GLUCOSIDASE INHIBITOR; AMINOGUANIDINE; APTAMER; ATORVASTATIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LIPID; NUCLEIC ACID; PIGMENT EPITHELIUM DERIVED FACTOR; PIOGLITAZONE; PROTEIN; SUGAR; TELMISARTAN; ADENOSINE DEAMINASE INHIBITOR; AGER PROTEIN, HUMAN; DPP4 PROTEIN, HUMAN;

AGING; ALZHEIMER DISEASE; ARTICLE; BLOOD LEVEL; CELL PROLIFERATION; CHEMICAL REACTION; CHEMICAL STRUCTURE; DESICCATION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG TARGETING; FIBROSIS; HUMAN; HYPERGLYCEMIA; INFLAMMATION; MACROMOLECULE; MOLECULAR INTERACTION; NEOPLASM; NONHUMAN; ORGAN INJURY; OSTEOPOROSIS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REACTION ANALYSIS; THROMBOSIS; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GENE EXPRESSION; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY;

ADENOSINE DEAMINASE INHIBITORS; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; ALZHEIMER DISEASE; APTAMERS, NUCLEOTIDE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIPEPTIDYL PEPTIDASE 4; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NEOPLASMS; OSTEOPOROSIS; OXIDATIVE STRESS;

EID: 84945940465     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2015.00067     Document Type: Article

References (131)

1. International Diabetes Federation. (2013) IDF Diabetes Atlas. 6th ed. Brussels, Belgium: International Diabetes Federation.
2. Yamagishi S, Imaizumi T. (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 11:2279-99.
3. Emerging Risk Factors Collaboration, et al. (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 364:829-41.
4. Yamagishi S, Matsui T, Fukami K. (2015) Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk. Rejuvenation Res. 18:48-56.
5. Takeuchi M, Yamagishi S. (2008) Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease. Curr. Pharm. Des. 14:973-8.
6. Yamagishi S. (2011) Role of advanced glycation end products (AGEs) in osteoporosis in diabetes. Curr. Drug Targets. 12:2096-102.
7. Loukine L, Waters C, Choi BC, Ellison J. (2012) Impact of diabetes mellitus on life expectancy and health-adjusted life expectancy in Canada. Popul. Health Metr. 10:7.
8. Turin TC, et al. (2102) NIPPON DATA80 Research Group: Diabetes and life expectancy among Japanese-NIPPON DATA80. Diabetes Res. Clin. Pract. 96:e18-22.
9. Rhodes ET, et al. (2012) Estimated morbidity and mortality in adolescents and young adults diagnosed with type 2 diabetes mellitus. Diabet. Med. 29:453-63.
10. Takeuchi M, et al. (2001) Immunological detection of a novel advanced glycation end-product. Mol. Med. 7:783-91.
11. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. (2015) Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 64:631-42.
12. DCCT/EDIC Research Group. (2014) Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study. Lancet Diabetes Endocrinol. 2:793-800.
13. Martin CL, Albers JW, Pop-Busui R. (2014) DCCT/EDIC Research Group: Neuropathy and related findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care. 37:31-8.
14. Nathan DM, et al. (2003) Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N. Engl. J. Med. 348:2294-303.
15. Nathan DM, et al. (2005) Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353:2643-53.
16. Nathan DM; DCCT/EDIC Research Group. (2014) The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study at 30 years: overview. Diabetes Care. 37:9-16.
17. Writing Group for the DCCT/EDIC Research Group, et al. (2015) Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 313:45-53.
18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359:1577-89.
19. Monnier VM, Kohn RR, Cerami A. (1984) Accelerated age-related browning of human collagen in diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 81:583-7.
20. Makita Z, et al. (1992) Hemoglobin-AGE: a circulating marker of advanced glycosylation. Science. 258:651-3.
21. Wolffenbuttel BH, Giordano D, Founds HW, Bucala R. (1996) Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet. 347:513-5.
22. Hricik DE, Wu YC, Schulak A, Friedlander MA. (1996) Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. Clin. Transplant. 10:568-73.
23. Sourris KC, Forbes JM. (2009) Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy: are these receptors valid therapeutic targets. Curr. Drug Targets. 10:42-50.
24. Yamagishi S, Nakamura K, Matsui T, Noda Y, Imaizumi T. (2008) Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication. Curr. Pharm. Des. 14:487-95.
25. Yamagishi S, Matsui T. (2010) Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front. Biosci. 2:1184-95.
26. Daffu G, et al. (2013) Radical roles for RAGE in the pathogenesis of oxidative stress in cardiovascular diseases and beyond. Int. J. Mol. Sci. 14:19891-910.
27. Fukami K, Yamagishi S, Okuda S. (2014) Role of AGEs-RAGE system in cardiovascular disease. Curr. Pharm. Des. 20:2395-402.
28. Ceriello A, Ihnat MA, Thorpe JE. (2009) Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications? J. Clin. Endocrinol. Metab. 94:410-5.
29. Chilelli NC, Burlina S, Lapolla A. (2013) AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view. Nutr. Metab. Cardiovasc. Dis. 23:913-9.
30. Yamagishi S. (2012) Potential clinical utility of advanced glycation end product cross-link breakers in age-and diabetes-associated disorders. Rejuvenation Res. 15:564-72.
31. Rizvi AA. (2009) Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am. J. Med. Sci. 55:659-65.
32. Lamon BD, Hajjar DP. (2008) Inflammation at the molecular interface of atherogenesis: an anthropological journey. Am. J. Pathol. 173:1253-64.
33. Yamagishi S, et al. (2007) Pigment epitheliumderived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept. Lett. 14:832-5.
34. Soro-Paavonen A, et al. (2010) Advanced glycation end-products induce vascular dysfunction via resistance to nitric oxide and suppression of endothelial nitric oxide synthase. J. Hypertens. 28:780-8.
35. Ueda S, Yamagishi S, Yokoro M, Okuda S. (2014) Role of asymmetric dimethylarginine in cardiorenal syndrome. Curr. Pharm. Des. 20:2448-55.
36. Ojima A, et al. (2013) Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocininduced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am. J. Pathol. 182:132-41.
37. Ando R, et al. (2013) Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. Diab. Vasc. Dis. Res. 10:436-41.
38. Ishibashi Y, et al. (2014) Irbesartan inhibits advanced glycation end product-induced increase in asymmetric dimethylarginine level in mesangial cells through its anti-oxidative properties. Int. J. Cardiol. 176:1120-2.
39. Bucala R, et al. (1994) Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. Proc. Natl. Acad. Sci. U. S. A. 191:9441-5.
40. Cai W, et al. (2004) High levels of dietary advanced glycation end products transform lowdensity lipoprotein into a potent redox-sensitive mitogen-activated protein kinase stimulant in diabetic patients. Circulation. 110:285-91.
41. Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. (2011) Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1. Horm. Metab. Res. 43:619-24.
42. Khera AV, et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N. Engl. J. Med. 364:127-35.
43. Takenaka K, Yamagishi S, Matsui T, Nakamura K, Imaizumi T. (2006) Role of advanced glycation end products (AGEs) in thrombogenic abnormalities in diabetes. Curr. Neurovasc. Res. 3:73-7.
44. Ishibashi Y, Matsui T, Ueda S, Fukami K, Yamagishi S. (2014) Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression. Cardiovasc. Diabetol. 13:60.
45. Ishibashi Y, Matsui T, Yamagishi S. (2014) Apixaban exerts anti-inflammatory effects in mesangial cells by blocking thrombin/protease-activated receptor-1 system. Thromb. Res. 134:1365-7.
46. Ishibashi Y, et al. (2015) Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 system. Thromb. Res. 135:770-3.
47. Yamagishi S, Fujimori H, Yonekura H, Yamamoto Y, Yamamoto H. (1998) Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells. Diabetologia. 41:1435-41.
48. Yamagishi S, Imaizumi T. (2005) Pericyte biology and diseases. Int. J. Tissue React. 27:125-35.
49. Yamagishi S, et al. (1997) Advanced glycation end products-driven angiogenesis in vitro: induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J. Biol. Chem. 272:8723-30.
50. Moulton KS. (2001) Plaque angiogenesis and atherosclerosis. Curr. Atheroscler. Rep. 3:225-33.
51. Nomura M, et al. (1995) Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J. Biol. Chem. 270:28316-24.
52. Yamagishi S, et al. (1999) Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab. Invest. 79:501-9.
53. Hoenig MR, Bianchi C, Rosenzweig A, Sellke FW. (2008) Decreased vascular repair and neovascularization with ageing: mechanisms and clinical relevance with an emphasis on hypoxiainducible factor-1. Curr. Mol. Med. 8:754-67.
54. Chen Q, Dong L, Wang L, Kang L, Xu B. (2009) Advanced glycation end products impair function of late endothelial progenitor cells through effects on protein kinase Akt and cyclooxygenase-2. Biochem. Biophys. Res. Commun. 381:192-7.
55. Scheubel RJ, et al. (2006) Depression of progenitor cell function by advanced glycation endproducts (AGEs): potential relevance for impaired angiogenesis in advanced age and diabetes. Exp. Gerontol. 41:540-8.
56. Bhatwadekar AD, et al. (2008) Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 49:1232-41.
57. Yamagishi S, Fujimori H, Yonekura H, Tanaka N, Yamamoto H. (1999) Advanced glycation endproducts accelerate calcification in microvascular pericytes. Biochem. Biophys. Res. Commun. 258:353-7.
58. Suga T, et al. (2011) Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells. J. Atheroscler. Thromb. 18:670-83.
59. Yamagishi S, Matsui T. (2010) Smooth muscle cell pathophysiology and advanced glycation end products (AGEs). Curr. Drug Targets. 11:875-81.
60. Yoon YW, et al. (2008) Pathobiological role of advanced glycation endproducts via mitogen-activated protein kinase dependent pathway in the diabetic vasculopathy. Exp. Mol. Med. 40:398-406.
61. Wu S, et al. (2008) Involvement of Na+/H+ exchanger 1 in advanced glycation end productsinduced proliferation of vascular smooth muscle cell. Biochem. Biophys. Res. Commun. 375:384-9.
62. Moore TC, et al. (2003) The role of advanced glycation end products in retinal microvascular leukostasis. Invest. Ophthalmol. Vis. Sci. 44:4457-64.
63. Lu M, et al. (1999) VEGF increases retinal vascular ICAM-1 expression in vivo. Invest. Ophthalmol. Vis. Sci. 40:1808-12.
64. Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Imaizumi T. (2006) Pigment epithelium-derived factor (PEDF) prevents diabetes-or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc. Res. 72:86-90.
65. Yamagishi S, Matsui T. (2011) Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Curr. Pharm. Biotechnol. 12:362-8.
66. Yamagishi S, Matsui T. (2010) Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid. Med. Cell Longev. 3:101-8.
67. Fukami K, Taguchi K, Yamagishi S, Okuda S. (2015) Receptor for advanced glycation endproducts and progressive kidney disease. Curr. Opin. Nephrol. Hypertens. 24:54-60.
68. Yamagishi S, et al. (2002) Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human-cultured mesangial cells. J. Biol. Chem. 277:20309-15.
69. Stieger N, Worthmann K, Schiffer M. (2011) The role of metabolic and haemodynamic factors in podocyte injury in diabetes. Diabetes Metab. Res. Rev. 27:207-15.
70. Fukami K, et al. (2013) Telmisartan inhibits AGEinduced podocyte damage and detachment. Microvasc. Res. 88:79-83.
71. Yamagishi S, et al. (2003) Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells. Kidney Int. 63:464-73.
72. Ojima A, Matsui T, Nishino Y, Nakamura N, Yamagishi S. (2015) Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts antiinflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis. Horm. Metab. Res. In press. 2015, Jan 22 [Epub ahead of print].
73. Nishikawa T, et al. (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 404:787-90.
74. Soro-Paavonen A, et al. (2008) Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes. Diabetes. 57:2461-9.
75. Yamamoto Y, et al. (2001) Development and prevention of advanced diabetic nephropathy in RAGEoverexpressing mice. J. Clin. Invest. 108:261-8.
76. Wendt TM, et al. (2003) RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 162:1123-37.
77. Flyvbjerg A, et al. (2004) Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. Diabetes. 53:166-72.
78. Jensen LJ, et al. (2006) Renal effects of a neutralising RAGE-antibody in long-term streptozotocindiabetic mice. J. Endocrinol. 188:493-501.
79. Kaji Y, et al. (2007) Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. Invest. Ophthalmol. Vis. Sci. 48:858-65.
80. Bierhaus A, et al. (2004) Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J. Clin. Invest. 114:1741-51.
81. Yamagishi S, et al. (2008) Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications. Expert. Opin. Investig. Drugs. 17:983-96.
82. Norton GR, Candy G, Woodiwiss AJ. (1996) Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocininduced diabetes mellitus in rats. Circulation. 93:1905-12.
83. Chang KC, et al. (2006) Aminoguanidine prevents arterial stiffening in a new rat model type 2 diabetes. Eur. J. Clin. Invest. 36:528-35.
84. Forbes JM, et al. (2004) Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 53:1813-23.
85. Forbes JM, et al. (2003) The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 17:1762-4.
86. Yamagishi S, et al. (2006) Pigment epitheliumderived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen speciesmediated vascular endothelial growth factor expression. J. Biol. Chem. 281:20213-20.
87. Yamagishi S, et al. (2008) Pigment epithelium-derived factor (PEDF): its potential therapeutic implication in diabetic vascular complications. Curr. Drug Targets. 9:1025-9.
88. Maeda S, et al. (2011) Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol. Res. 63:241-8.
89. Yamagishi S, Matsui T. (2014) Pigment epithelium-derived factor (PEDF) and cardiometabolic disorders. Curr. Pharm. Des. 20:2377-86.
90. Yamagishi S, Nakamura K, Matsui T. (2007) Potential utility of telmisartan, an angiotensin II type 1 receptor blocker with peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-modulating activity for the treatment of cardiometabolic disorders. Curr. Mol. Med. 7:463-9.
91. Yamagishi S, et al. (2005) Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression. FEBS Lett. 579:4265-70.
92. Fukami K, et al. (2004) AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int. 66:2137-47.
93. Matsui T, Nishino Y, Maeda S, Takeuchi M, Yamagishi S. (2011) Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells. Microvasc. Res. 81:269-73.
94. Fukami K, et al. (2013) Telmisartan inhibits AGE-induced podocyte damage and detachment. Microvasc. Res. 88:79-83.
95. Yamagishi S, Matsui T. (2011) Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes. Curr. Pharm. Des. 17:4379-85.
96. Yamagishi SI, Fukami K, Matsui T. (2015) Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc. Diabetol. 14:2.
97. Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S. (2013) Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc. Diabetol. 12:125.
98. Nakashima S, Matsui T, Takeuchi M, Yamagishi SI. (2014) Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis. Horm. Metab. Res. 46:717-21.
99. Matsui T, et al. (2015) Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis. Lab. Invest. 95:525-33.
100. Kaida Y, et al. (2013) DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy. Diabetes. 62:3241-50.
101. Ojima A, Oda E, Higashimoto Y, Matsui T, Yamagishi S. (2014) DNA aptamer raised against advanced glycation end products inhibits neointimal hyperplasia in balloon-injured rat carotid arteries. Int. J. Cardiol. 171:443-6.
102. Takeuchi M, et al. (2000) Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J. Neuropathol. Exp. Neurol. 59:1094-105.
103. Yamamoto Y, et al. (2007) Short-chain aldehydederived ligands for RAGE and their actions on endothelial cells. Diabetes Res. Clin. Pract. 77(3 Suppl):S30-40.
104. Yamagishi S, et al. (2006) Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism. 55:1227-31.
105. Nakamura K, et al. (2007) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects. Clin. Exp. Med. 7:188-90.
106. Nakamura K, et al. (2008) Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes. Microvasc. Res. 76:52-6.
107. Yanagisawa K, et al. (2014) Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargineinjected diabetic patients. Diabetes Metab. Res. Rev. 30:693-700.
108. Enomoto M, et al. (2006) Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans. Metabolism. 55:912-7.
109. Yamagishi S, et al. (2007) Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population. Horm. Metab. Res. 39:845-8.
110. Yamagishi S, et al. (2009) Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects. Clin. Cardiol. 32:E12-5.
111. Nakamura K, et al. (2008) Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes. Diabetes Metab. Res. Rev. 24:109-14.
112. Nakamura T, et al. (2009) Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock. Pharmacol. Res. 60:515-8.
113. Nakamura T, et al. (2009) Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism. 58:1624-8.
114. Hyogo H, et al. (2007) Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J. Gastroenterol. Hepatol. 22:1112-9.
115. Tahara N, Imaizumi T, Takeuchi M, Yamagishi SI. (2010) Insulin resistance is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men. Oxid. Med. Cell. Longev. 3:262-265.
116. Tahara N, et al. (2012) Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc. Ther. 30:42-8.
117. Yamagishi S, Matsui T, Adachi H, Takeuchi M. (2010) Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmacol. Res. 61:103-7.
118. Tahara N, et al. (2013) Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. Clin. Biochem. 46:300-3.
119. Tahara N, et al. (2015) Clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT. J. Clin. Endocrinol. Metab. 100:E739-47.
120. Tahara N, et al. (2012) Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [(18)F]fluorodeoxyglucose positron emission tomography. Diabetes Care. 35:2618-25.
121. Kajikawa M, et al. (2015) Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care. 38:119-25.
122. Ueda S, et al. (2012) Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc. Ther. 30:249-54.
123. Fukushima Y, et al. (2013) Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: the JAPAN-ACS sub-study. Cardiovasc. Diabetol. 12:5.
124. Jinnouchi Y, et al. (2006) Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin. Exp. Med. 6:191-3.
125. Kimura Y, et al. (2010) Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J. Gastroenterol. 45:750-7.
126. Nakamura T, et al. (2010) Atorvastatin reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs). Oxid. Med. Cell. Longev. 3:304-7.
127. Sakata K, et al. (2013) Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE)-receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. Diabetes Metab. Res. Rev. 229:624-30.
128. Tsunosue M, et al. (2010) An alpha-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes. Clin. Exp. Med. 10:139-41.
129. Ahmed N, et al. (2005) Assay of advanced glycation endproducts in selected beverages and food by liquid chromatography with tandem mass spectrometric detection. Mol. Nutr. Food Res. 49:691-9.
130. Matsui T, Oda E, Higashimoto Y, Yamagishi SI. (2015) Glyceraldehyde-derived pyridinium (GLAP) evokes oxidative stress and inflammatory and thrombogenic reactions in endothelial cells via the interaction with RAGE. Cardiovasc. Diabetol. 14:1.
131. Usui T, Shimohira K, Watanabe H, Hayase F. (2007) Detection and determination of glyceraldehyde-derived pyridinium-type advanced glycation end products in streptozotocininduced diabetic rats. Biosci. Biotechnol. Biochem. 71:442-8.